Multinational pharmaceutical company, GlaxoSmithKline (GSK) has announced the recall of over 590,000 Salbutamol (Ventolin) inhalers from the US market, saying there could be issues with the delivery technique.
The recall is for three lots of Ventolin HFA 200D inhalers with lot numbers 6ZP0003, 6ZP9944 and 6ZP9848.
The inhalers, according to reports, have been distributed to hospitals, pharmacies, retailers and wholesalers in the United States.
“There is attainable risk that the affected inhalers could potentially not deliver the stated number of actuations,” according to GSK spokesman Juan Carlos Molina. “We continue to investigate the situation in order to identify the root lead to and implement appropriate corrective and preventative actions.”
The recall is not directed at individuals, but those with inhalers from the recalled lots have been advised to contact the company.
